March 2nd 2022
Closing out their discussion on the management of chronic myeloid leukemia, experts share practical advice and excitement for novel strategies.
February 23rd 2022
Moshe Talpaz, MD, discusses best practices in monitoring patients with CML and applying multidisciplinary care.
Daniel DeAngelo, MD, PhD, provides his perspective on improving CML care through dose adjustment or treatment discontinuation.
February 16th 2022
An overview of the general toxicities patients may experience while undergoing therapy for chronic myeloid leukemia.
A brief review of asciminib’s toxicity profile and how to best manage adverse events in patients with chronic myeloid leukemia.
February 9th 2022
Experts share their personal experience with asciminib as later-line therapy for patients with chronic myeloid leukemia.
Shared insight on asciminib’s role in chronic myeloid leukemia in light of available clinical data.
February 2nd 2022
Jorge Cortes, MD, breaks down third-line treatment options for patients who progress with chronic myeloid leukemia.
A brief review of the inherent challenges in guiding patients through several lines of therapy for chronic myeloid leukemia.
January 26th 2022
Considerations for selecting optimal second-line therapy for chronic myeloid leukemia when a patient progresses.
Daniel DeAngelo, MD, PhD, highlights the role that tyrosine kinase inhibitors play in the CML treatment paradigm.
January 19th 2022
Key opinion leader perspectives on assessing a patient’s response to therapy for chronic myeloid leukemia.
Shared insight on chromosomal abnormalities and genetic alterations that influence the disease course and management of CML.
December 14th 2021
Expert overview of chronic myeloid leukemia, including considerations for the unmet needs in management as they exist today.
September 20th 2021
The panel of experts discuss the clinical differences between well-differentiated systemic mastocytosis and chronic mast cell leukemia.
September 13th 2021
The panel of experts in SM discuss the diagnosis and treatment of a 68-year-old female with mast cell leukemia.
September 7th 2021
Dan DeAngelo, MD, PhD, presents the case of a patient with indolent systemic mastocytosis and urticaria pigmentosa.
A panel of experts share their reactions to the approval of avapritinib and discuss the clinical implications.
August 30th 2021
Dan DeAngelo, MD, PhD, reviews key efficacy data from the phase II PATHFINDER study.
Patricia Lugar, MD, MS, shares an allergist’s perspective regarding treatment algorithms and supportive care recommendations for patients with systemic mastocytosis.